Recording-2025-02-07T07:06:16.035Z
Introduction to Lipid Lowering Medications
Purpose: To decrease cholesterol and triglyceride levels in the body.
Common Classes: Statins and fibrates.
Other Medications: Bile acid resins, niacin (Vitamin B3), ezetimibe, PCSK9 inhibitors.
Importance of Cholesterol
Function: Critical component of cell membranes and has roles in synthesizing steroid hormones, vitamin D, and bile.
Sources of Cholesterol:
Dietary: Obtained from food (e.g., fats from fries).
Endogenous: Synthesized by the liver.
Cholesterol Absorption and Transport
Process:
Dietary fats and cholesterol are absorbed in the small intestine.
They are packaged into lipoproteins (water-soluble) to be transported in the bloodstream.
Lipoproteins:
Chylomicrons: Largest and least dense; transport dietary cholesterol from intestines to lymphatic system and bloodstream.
Cholesterol Synthesis in the Liver
Mavalinate Pathway:
Begins with two acetyl CoA molecules joining via acetyl CoA acyl transferase to form four-carbon acetyl acetyl CoA.
Combined by HMG CoA synthase into HMG CoA (six-carbon).
HMG CoA reductase converts HMG CoA into mevalonate (rate-limiting step).
Outcome: Mevalonate is a precursor to cholesterol.
Lipoprotein Types and Functions
VLDL (Very Low-Density Lipoproteins):
Packaged with triglycerides and cholesterol; transport to body tissues.
After delivering triglycerides, they become LDL.
LDL (Low-Density Lipoproteins):
Smaller, denser; deliver cholesterol to peripheral tissues.
HDL (High-Density Lipoproteins):
Small but dense; transport excess cholesterol back to the liver.
Function: Opposes the role of LDL in cholesterol transport.
Implications of LDL Levels
Cholesterol Buildup:
Excess LDL leads to cholesterol accumulation in tissues, particularly the endothelium of blood vessels.
Results in the formation of plaques, increasing the risk of cardiovascular diseases (strokes, myocardial infarctions, peripheral vascular disease).
Miscellaneous Lipid Lowering Agents
1. Bile Acid Resins
Examples: Cholestyramine, Cholestopol, Cholesevelam.
Mechanism:
Bind to bile acids in the intestine, preventing their reabsorption.
Induces liver to produce more bile salts from cholesterol.
Increases LDL receptor numbers, enhancing LDL uptake and lowering cholesterol.
Use: Often combined with statins; primarily lower LDL.
Side Effects: Gastrointestinal upset, decreased absorption of fat-soluble vitamins (A, D, E, K).
2. Niacin (Vitamin B3)
Mechanism:
Inhibits lipoprotein lipase in adipose tissue, reducing free fatty acid release.
Leads to decreased VLDL and LDL levels.
Can moderately increase HDL.
Side Effects: Flushing (red face and itching), hyperglycemia, elevated uric acid levels.
3. Ezetimibe
Mechanism:
Blocks Niemann-Pick C1-like 1 (NPC1L1) protein, reducing cholesterol absorption in the intestine.
Does not affect VLDL or HDL levels.
Use: Typically combined with statins.
Side Effects: Gastrointestinal upset, rare liver damage.
4. PCSK9 Inhibitors
Examples: Ilyrolcumab, Evolocumab.
Mechanism:
Antibodies that bind PCSK9 protein, preventing degradation of LDL receptors.
Increases LDL receptor availability, reducing LDL levels in the bloodstream and moderately affecting VLDL and HDL.
Administration: Injection every 2-4 weeks.
Side Effects: Muscle pain, neurocognitive effects (delirium, dementia).
Conclusion
Significance: A vital role in managing cholesterol levels and preventing cardiovascular diseases through various mechanisms.
Combination Therapies: Often used together to enhance efficacy and target different pathways in lipid metabolism.